(3R)-1-azabicyclo[2.2.2]octan-3-ol CAS:25333-42-0

Chemical Name: (3R)-1-azabicyclo[2.2.2]octan-3-ol
CAS.NO:  25333-42-0
Synonyms:
(R)-(-)-3-Quinuclidinol
3-Quinuclidinol l-form
dl-3-Quinuclidinol

Molecular Formula: C7H13NO
Molecular Weight:   127.18400

Physical and Chemical Properties:
Density: 1.13g / cm3
Boiling point: 120ºC (27 mmHg)
Melting point: 217-224ºC
Flash point: 97.7 ± 21.3 ° C
Refractive index: 1.549

Specification:
Appearance:  White – beige powder
Purity:≥99.0%
Loss on drying:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
Hypotensive. Synthon for preparation of cholinergic receptor ligands and anesthetics.Intermediates of Aclidinium bromide CAS:320345-99-1.

We are professional (3R)-1-azabicyclo[2.2.2]octan-3-ol manufacturer and dl-3-Quinuclidinol supplier in China, We offer quality (3R)-1-azabicyclo[2.2.2]octan-3-ol you can fully trust, also we have India factory and producer of (3R)-1-azabicyclo[2.2.2]octan-3-ol,Pls send inquiry of 3-Quinuclidinol l-form CAS:25333-42-0 to info@nbinno.com if you have any interests, thank you!


Related News: The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.2-Acetyl-1-ethylpyrrole CAS:39741-41-8 The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.2,7-Dihydroxynaphthalene Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.(R)-4,5,6,7-Tetrahydro-benzothiazole-2,6-diamine CAS:106092-11-9 Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.